Intradigm Corporation
Palo Alto
About Intradigm Corporation
Private biotechnology company that develops systematic RNA interference (RNAi) therapeutics for the treatment of serious diseases with an initial focus on oncology. The company's expertise in drug development and delivery serves as the foundation of Intradigm RNAi platform. In particular, the company proprietary RNAi Nanoplex delivery technology is unique in its ability to enable the targeted delivery of RNAi therapeutics to specific tissues through systemic administration of the drug product.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $37.4M
- Funding stage: M&A
- Last round: Series B (Jan 2009)
- Website: intradigm.com
- Phone: (650) 855 9696
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/intradigm-corporation-3314381 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.